8-K: Milestone Pharma Nears CARDAMYST FDA Decision, Boosts Cash

Milestone Pharmaceuticals reported Q3 2025 financial results, highlighted a December 13, 2025 PDUFA date for CARDAMYST, and strengthened its balance sheet for a potential launch.

Summary

• The PDUFA target date for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) is December 13, 2025.
• Cash, cash equivalents, and short-term investments totaled $82.6 million as of September 30, 2025, an increase from $69.7 million as of December 31, 2024.
• An underwritten public offering was completed in July 2025, providing approximately $48.7 million in net proceeds.
• An amended Royalty Purchase Agreement in July 2025 includes a $75 million royalty payment contingent upon FDA approval of CARDAMYST.
• Commercial expenses significantly increased to $4.6 million in Q3 2025 from $1.9 million in Q3 2024, reflecting intensified pre-launch activities.
• Net loss for Q3 2025 was $11.9 million, compared to $9.4 million for the prior year period.
• New clinical data for etripamil, presented at the American Heart Association Scientific Sessions 2025 on November 10, showed consistent efficacy and safety across multiple study phases.
• The Phase 3 protocol for etripamil in Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) (ReVeRA-301) has been finalized, with plans to leverage PSVT NDA data for a potential second indication.

Sentiment

Score: 7

Explanation: The company is on track for a critical FDA decision for its lead product, CARDAMYST, with a clear PDUFA date. It has significantly strengthened its financial position through an equity offering and a royalty agreement to support a commercial launch. Positive clinical data and advancement of a second indication (AFib-RVR) further contribute to a positive outlook. However, increased net losses due to pre-launch activities and the inherent risks associated with regulatory approval and commercialization temper the overall sentiment.

Positives

• The PDUFA target date of December 13, 2025, for CARDAMYST in PSVT indicates a near-term regulatory decision, bringing the company closer to potential commercialization.
• A strong cash position of $82.6 million as of September 30, 2025, provides substantial resources for the anticipated launch and ongoing operations.
• The successful equity offering generated approximately $48.7 million in net proceeds, bolstering the company's financial runway.
• The amended Royalty Purchase Agreement secures a $75 million payment upon FDA approval, further enhancing financial stability for the launch.
• Increased pre-launch activities and strengthened commercialization capabilities demonstrate readiness for a rapid market entry following potential FDA approval.
• Positive new clinical data for etripamil, presented at AHA Scientific Sessions 2025, supports its efficacy and safety profile.
• Etripamil was referenced in recent AHA ACLS Guidelines, highlighting its potential to influence future treatment algorithms.
• The finalization of the Phase 3 protocol for etripamil in AFib-RVR (ReVeRA-301) advances the pipeline for a potential second indication, expanding the drug's market opportunity.

Negatives

• Net loss increased to $11.9 million for Q3 2025, compared to $9.4 million for Q3 2024.
• The net loss for the nine months ended September 30, 2025, was $45.6 million, a significant increase from $29.2 million for the same period in 2024.
• Commercial expenses rose substantially to $4.6 million in Q3 2025 from $1.9 million in Q3 2024, contributing to higher operating losses.
• No revenue was reported for the third quarter ended September 30, 2025, or for the third quarter of 2024, indicating the company remains pre-revenue.

Risks

• Uncertainty regarding the outcomes of future interactions with the FDA, including the potential approval of the NDA for CARDAMYST for PSVT.
• Risks related to the ability to receive additional cash proceeds from warrants issued in the offering.
• Uncertainty regarding the ability to receive the $75.0 million royalty payment under the Royalty Purchase Agreement on the timeline provided, or at all.
• Risks related to the sufficiency of capital resources and the ability to raise additional capital in the current economic climate.
• Uncertainties related to the timing of initiation, enrollment, completion, evaluation, and results of clinical trials for etripamil in AFib-RVR.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine, and ongoing disputes in Israel and Gaza.
• Risks related to pandemics and public health emergencies.

Future Outlook

Milestone Pharmaceuticals is optimistic about the potential FDA approval of CARDAMYST for PSVT by the PDUFA date of December 13, 2025, and plans for a quick commercial launch. The company also intends to advance etripamil into a pivotal Phase 3 program for AFib-RVR, leveraging existing PSVT data for a potential second indication.

Management Comments

• "We are approaching our December 13 Prescription Drug User Fee Act (PDUFA) date with optimism and excitement for the opportunity to bring CARDAMYST (etripamil) nasal spray to patients suffering from symptomatic PSVT." Joseph Oliveto, President and Chief Executive Officer.
• "Our team has recently increased our pre-launch activities to better enable market readiness." Joseph Oliveto, President and Chief Executive Officer.
• "We strengthened our balance sheet with a successful equity financing last quarter, and together with the $75 million royalty payment upon FDA approval, we believe we have resources in place to drive a successful commercial launch." Joseph Oliveto, President and Chief Executive Officer.

Industry Context

The potential approval of CARDAMYST would introduce a novel, self-administered calcium channel blocker nasal spray for PSVT, addressing an unmet need for on-demand care outside of a medical setting. This aligns with broader trends in cardiology towards patient empowerment and convenient treatment options for episodic conditions. The reference in AHA ACLS Guidelines further validates its potential impact on future treatment algorithms, positioning Milestone as an innovator in cardiovascular care.

Stakeholder Impact

• Shareholders: Potential for significant value creation if CARDAMYST receives FDA approval and achieves successful commercialization. Dilution from recent equity offering.
• Patients (PSVT & AFib-RVR): Potential access to a novel, self-administered rapid response therapy, offering greater control over their condition and reducing the need for immediate medical oversight.
• Healthcare Providers: A new treatment option to enable on-demand care and patient self-management for PSVT and potentially AFib-RVR.
• Employees: Increased operational expenditures and pre-launch activities suggest a growing team and increased workload in preparation for commercialization.

Next Steps

• Await FDA decision on CARDAMYST (etripamil) NDA for PSVT by December 13, 2025.
• Execute commercial launch of CARDAMYST quickly following potential FDA approval.
• Initiate a pivotal Phase 3 program (ReVeRA-301) for etripamil in AFib-RVR.
• Potentially submit a supplemental NDA for etripamil in AFib-RVR, leveraging PSVT NDA data.

Key Dates

Recommendation

The company is at a critical juncture with a PDUFA date for CARDAMYST less than a month away. While the financial position has been strengthened and pre-launch activities are ramping up, the outcome of the FDA decision remains a binary event. A positive approval would likely lead to a significant upside, while a rejection or further delay would be detrimental. Given the proximity to the decision and the inherent regulatory risk, a 'hold' recommendation is prudent for investors to await the FDA's verdict before making further investment decisions. The increased net loss, while expected for pre-commercialization, adds to the risk profile.

Keywords

Milestone Pharmaceuticals, MIST, CARDAMYST, etripamil, PSVT, Paroxysmal Supraventricular Tachycardia, AFib-RVR, Atrial Fibrillation, FDA approval, PDUFA, Nasal Spray, Biopharmaceutical, Clinical Trials, Q3 2025 Earnings, Financial Results, Equity Offering, Royalty Agreement